Skip to main content

Advertisement

Figure 1 | BMC Infectious Diseases

Figure 1

From: Hepatic profile analyses of tipranavir in Phase II and III clinical trials

Figure 1

Kaplan-Meier estimates for time-to-first Grade 3/4 ALT/AST elevations and to first hepatobiliary serious adverse events (SAEs) among TPV/r recipients by baseline risk group. Log-rank test p-value comparing -LD vs. +LD:. Incidence of Hepatic SAEs p = 0.0125. Incidence of DAIDS Grade 3/4 ALT/AST p = 0.0072. TPV/r +LD patients with Grade 3/4 ALT/AST = TPV/r patients co-infected with HBV/HCV or with baseline ALT/AST DAIDS >1, time-to-first DAIDS ὅ3 ALT/AST. TPV/r -LD patients with Grade 3/4 ALT/AST = TPV/r patients not co-infected with HBV/HCV and with baseline ALT/AST DAIDS ὄ1, time-to-first DAIDS ὅ3 ALT/AST. TPV/r +LD patients with hepatic SAE = TPV/r patients co-infected with HBV/HCV or with baseline ALT/AST DAIDS >1, time-to-first onset date of hepatic SAE. TPV/r -LD patients with hepatic SAE = TPV/r patients not co-infected with HBV/HCV and with baseline ALT/AST DAIDS ὄ1, time-to-first onset date of hepatic SAE. +LD = patients with underlying liver disease (baseline evidence of active HBV/HCV infection or ALT/AST DAIDS >1); -LD = patients with no apparent liver disease (absence of active HBV/HCV infection and ALT/AST Grade ≤ 1); ALT = alanine aminotransferase; AST = aspartate aminotransferase; DAIDS = Division of AIDS; HBV = hepatitis B virus; HCV = hepatitis C virus; TPV/r = ritonavir-boosted tipranavir.

Back to article page